Krystal Biotech (KRYS) EBIT Margin (2017 - 2026)
Krystal Biotech's EBIT Margin was 55.87% in Q3 2026, up 13.56 percentage points from 42.30% a year earlier and up 6.87 percentage points from the prior quarter.
Powered by 
Analysis
Krystal Biotech (KRYS) EBIT Margin (2017 - 2026) Analysis & Trends
On a trailing twelve-month basis, Krystal Biotech's EBIT Margin was 48.40% through Sep 30, 2026, up 5.95 percentage points year-over-year; for FY2025, it came in at 41.45%, up 18.82 percentage points from FY2024.
- In earlier years, EBIT Margin was 22.63% in FY2024 (+238.84 pp) and -216.21% in FY2023.
- The Q3 2026 figure marks the highest quarterly EBIT Margin in data going back to Q3 2023.
- Compared with a year earlier, EBIT Margin has increased for three straight quarters, with an average year-over-year change of +20.05 percentage points over the last eight quarters.
- The best year-over-year quarter for EBIT Margin over five years was Q3 2024 (a gain of 330.60 percentage points); the worst was Q4 2025 (a drop of 4.08 percentage points).
- Per Business Quant data, KRYS's EBIT Margin in the three quarters before Q3 2026 was 49.00% (Q2 2026), 46.12% (Q1 2026) and 41.33% (Q4 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 34.46% |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 24.35% |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 36.01% |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 30.74% |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 29.12% |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 35.79% |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 41.71% |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 32.98% |
| 10 | Krystal Biotech | 9.08 Bn | 5.67 Bn | 119.79 Mn | 55.87% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 55.87% |
| Jun 30, 2026 | 49.00% |
| Mar 31, 2026 | 46.12% |
| Dec 31, 2025 | 41.33% |
| Sep 30, 2025 | 42.30% |
| Jun 30, 2025 | 41.02% |
| Mar 31, 2025 | 41.10% |
| Dec 31, 2024 | 45.41% |
| Sep 30, 2024 | 26.80% |
| Jun 30, 2024 | 12.18% |
| Mar 31, 2024 | -14.75% |
| Dec 31, 2023 | 7.71% |
| Sep 30, 2023 | -303.80% |
| Jun 30, 2022 | -4,457.83% |
| Mar 31, 2022 | -19,541.63% |
| Dec 31, 2021 | -31,251.43% |
| Sep 30, 2021 | -24,844.44% |
| Jun 30, 2021 | -54,643.33% |
| Mar 31, 2021 | -43,493.94% |
| Dec 31, 2020 | -28,162.16% |
API Access
Krystal Biotech EBIT Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebit-margin&ticker=KRYS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebit-margin", "ticker": "KRYS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebit-margin&ticker=KRYS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();